Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
REGN-5093M114 by Regeneron Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval
REGN-5093M114 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to...